Recent advances in the pharmacotherapy of smoking

JAMA

Volumn 281, Issue 1, 1999, Pages 72-76

  Hughes, John R ^d   Goldstein, Michael G ^a   Hurt, Richard D ^b   Shiffman, Saul ^c  

^a BROWN UNIVERSITY   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; NICOTINE;

ARTICLE; BEHAVIOR THERAPY; CLINICAL PROTOCOL; DRUG CHOICE; DRUG EFFICACY; DRUG FORMULATION; HUMAN; INSOMNIA; PRIORITY JOURNAL; SMOKING; SMOKING CESSATION; TREATMENT PLANNING; XEROSTOMIA;

EID: 0033528103     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.281.1.72     Document Type: Article

References (56)

1. Hughes JR, Fiester S, Goldstein MG, Resnick MP, Rock N, Ziedonis D. American Psychiatric Association practice guideline for the treatment of patients with nicotine dependence. Am J Psychiatry. 1996; 153(suppl):S1-S31.
2. Smoking Cessation Clinical Practice Guideline Panel and Staff. The Agency for Health Care Policy and Research Smoking Cessation Clinical Practice Guideline. JAMA. 1996;275:1270-1280.
3. Shiftman S, Pinney JM, Gitchell J, Burton SL, Lara EA. Public health benefit of over-the-counter nicotine medications. Tob Control. 1997;6:306-310.
4. Hughes JR. Pharmacotherapy for smoking cessation: unvalidated assumptions, anomalies and suggestions for further research. J Consult Clin Psychol. 1993;61:751-760
5. Fagerstrom K-O, Kunze M, Schoberberger JC, et al. Nicotine dependence versus smoking prevalence. Tob Control. 1996;5:52-56.
6. Bums D, Benowitz NL, Connolly G, et al. What should be the elements of any settlement with the tobacco industry? Tob Control. 1997;6:1-4.
7. Baillie A, Mattick RP, Hall W, Webster P. Metaanalytic review of the efficacy of smoking cessaton interventions. Drug Alcohol Rev. 1994;13:157-170.
8. Schwartz JL. Methods of smoking cessation. Med Clin North Am. 1992;76:451-476.
9. Law M, Tang JL. An analysis of the effectiveness of interventions intended to help people stop smoking. Arch Intern Med. 1995;155:1933-1941.
10. Kottke TE, Battista RN, DeFriese GH, Brekke ML. Attributes of successful smoking cessation interventions in medical practice. JAMA. 1988;259:2882-2889.
11. Abrams DB, Orleans CT, Niaura RS, Goldstein MC, Velicer W, Prochaska JO. Treatment issues: towards a stepped care model. Tob Control. 1993;2(suppl):S17-S37.
12. Nicoderm data summary. Paper presented at meeting of the Nonprescription Drug Advisory Committee of the FDA; April 19, 1996; Bethesda, Md.
13. OTC Nicorette data summary. Paper presented at: meeting of the Nonprescription Drug Advisory Committee of the FDA; September 18,1995; Bethesda, Md.
14. Burton SL, Kemper KE, Baxter TA, Shiffman S, Gitchell J, Currence C. Impact of promotion of the great American smokeout and availability of over-the-counter nicotine medications, 1996. MMWR Morb Mortal Wkly Rep. 1997;46:867-871.
15. Schneider NG, Jarvik ME, Forsythe AB, Read LL, Elliott ML, Schweiger A. Nicotine gum in smoking cessation. Addict Behav. 1983;8:253-261.
16. Hays JT, Croghan IT, Offord KP, et al. Over-the-counter (OTC) transdermal nicotine patch therapy. J Addict Dis. 1997;16:136.
17. Leischow SJ, Castellini S, Merikle E. The efficacy of nicotine patch as an over-the-counter medication. J Addict Dis. 1997;16:140.
18. Sonderskov J, Olsen J, Sabroe S, Meillier L, Overvad K. Nicotine patches in smoking cessation. Am J Epidemiol. 1997;145:309-318.
19. Hughes JR. Combining behavioral therapy and pharmacotherapy for smoking cessation: an update. In: Onken LS, Blaine JD, Boren JJ, eds. Integrating Behavior Therapies With Medication in the Treatment of Drug Dependence: NIDA Research Monograph. Washington, DC: US Government Printing Office; 1995:92-109. Monograph 150.
20. Lichtenstein E, Glasgow RE, Lando HA, OssipKlein DJ, Boles SM. Telephone counseling for smoking cessation. Health Educ Res. 1996;11:243-257.
21. Nicotrol data summary. Paper presented at: meeting of the Nonprescription Drug Advisory Committee of the FDA; April 19,1996; Bethesda, Md.
22. Killen JD, Fortmann SP, Newman B, Varady A. Evaluation of a treatment approach combining nicotine gum with self-guided behavioral treatments for smoking relapse prevention. J. Consult Clin Psychol. 1990;58:85-92.
23. Hughes JR. Dependence potential and abuse liability of nicotine replacement therapies. Biomed Pharmacother. 1989;43:11-17.
24. Hatsukami DK, Huber M, Callies A, Skoog K. Physical dependence on nicotine gum: effect of duration of use. Psychopharmacology. 1993;111:449-456.
25. Hughes JR. Dependence on and abuse of nicotine replace: an update. In: Benowitz NL, ed. Nicotine Safety and Toxicity. New York, NY: Oxford University Press Inc; 1998:147-160.
26. Murray RP, Bailey WC, Daniels K, et al. Safety of nicotine polacrilex gum used by 3,094 participants in the Lung Health Study. Chest. 1996;109:438-445.
27. Hughes JR. Risk/benefit of nicotine replacement in smoking cessation. Drug Safety. 1993;8:49-56.
28. Benowitz NL. Nicotine replacement therapy during pregnancy. JAMA. 1991;266:3174-3177.
29. Miller LG. Cigarettes and drug therapy: pharmacokinetic and pharmacodynamic considerations. Clin Pharm. 1990;9:125-135.
30. Fagerstrom K-O, Schneider NG, Lunell E. Effectiveness of nicotine patch and nicotine gum as individual versus combined treatments for tobacco withdrawal symptoms. Psychopharmacology. 1993;111:271-277.
31. Puska P, Korhonen HJ, Vartiaaninen E, Utjanheimo EL, Gustavsson G, Westin A. Combined use of nicotine patch and gum compared with gum alone in smoking cessation. Tob Control. 1995;4:231-235.
32. Kornitzer M, Boutsen M, Dramaix M, Thijs J, Gustavsson G. Combined use of nicotine patch and gum in smoking cessation. Prev Med. 1995;24:41-47.
33. Fagerstrom K-O. Combined use of nicotine replacement products. Health Values. 1994;18:15-20.
34. Benowitz N, Gourlay S. Cardiovascular toxicity of nicotine: implications for nicotine replacement therapy. J Am Coll Cardiol. 1997;29:1422-1431.
35. Jimenez-Ruiz C, Kunze M, Fagerstrom K-O. Nicotine replacement: a new approach to reduce tobacco-related harm. Eur Respir J. 1998;11:473-479.
36. Foulds J. Nicorette nasal spray: a novel nicotine therapy. Prescriber. 1994;19:21-25.
37. Schneider NG, Lunell E, Olmstead RE, Fagerstrom K-O. Clinical pharmacokinetics of nasal nicotine delivery: a review and comparison to other nicotine systems. Clin Pharmacokinet 1996;31:65-80.
38. Gourlay SG, Benowitz NL. Arteriovenous differences in plasma concentration of nicotine and catecholamines and related cardiovascular effects after smoking, nicotine nasal spray, and intravenous nicotine. Clin Pharmacol Ther. 1997;62:453-463
39. Blondal T, Franzon M, Westin A A double-blind randomized trial of nicotine nasal spray as an aid in smoking cessation. Eur Respir J. 1997;10:1585-1590.
40. Hjalmarson A, Franzon M, Westin A, Wiklund O. Effect of nicotine nasal spray on smoking cessation. Arch Intern Med. 1994;154:2567-2572.
41. Schneider NG, Olmstead R, Mody FV, et al. Efficacy of a nicotine nasal spray in smoking cessation: a placebo-controlled, double-blind trial. Addiction. 1995;90:1671-1682.
42. Leischow SJ, Nilsson F, Franzon M, Hill A, Otte P, Merikle EP. Efficacy of the nicotine inhaler as an adjunct to smoking cessation. Am J Health Behav. 1996;20:364-371.
43. Mikkelsen EJ, Tennesen P, Ewald T, Clemmensen P. Routine smoking cessation with 4 nicotine regimens in a lung clinic. Eur Respir J. 1995;8:112S.
44. Schneider NG, Olmstead R, Nilsson F, Mody FV, Franzon M, Doan K. Efficacy of a nicotine inhaler in smoking cessation: a double-blind, placebo-controlled trial. Addiction. 1996;91:1293-1306.
45. Tonnesen P, Norregaard J, Mikkelsen K, Jorgensen S, Nilsson F. A double-blind trial of a nicotine inhaler for smoking cessation. JAMA. 1993;269:1268-1271.
46. Ferry LH, Burchette RJ. Efficacy of bupropion for smoking cessation in non-depressed smokers. J Addict Dis. 1994;13:249.
47. Sutherland G, Stapleton JA, Russell MAH, et al. Randomised controlled trial of nasal nicotine spray in smoking cessation. Lancet. 1992;340:324-329.
48. Schuh KJ, Schuh LM, Henningfield JE, Stitzer ML. Nicotine nasal spray and vapor inhaler: abuse liability assessment. Psychopharmacology. 1997;130:352-361.
49. Bergstrom M, Nordberg A, Lunell E, Antoni G, Langstrom B. Regional deposition of inhaled 11C-nicotine vapor in the human airway as visualized by positron emission tomography. Clin Phamacol Ther. 1995;57:309-317.
50. Ascher JA, Cole JO, Colin J, et al. Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatr. 1995;56:395-401.
51. Hayford KE, Patten CA, Rummans TA, et al. Effectiveness of bupropion for smoking cessation in smokers with a former history of major depression or alcoholism. Br J Psychiatry. In press.
52. Heishman SJ, Henningfield JE, Kendler KS. et al. Conference summary: Society for Research on Nicotine and Tobacco. Addiction. 1998;93:907-923.
53. Hurt RD, Sachs DPL, Glover ED, et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med. 1997;337:1195-1202.
54. Fiore MC, BakerTB. Smoking cessation treatment and the good doctor club. Am J Public Health. 1995; 85:161-163.
55. Gourtay SG, Forbes A, Marriner T, Pethica D, McNeil JJ. Double blind trial of repeated treatment with transdermal nicotine for relapsed smokers. BMJ. 1995;311: 363-366.
56. Tonnesen P, Norregaard J, Sawe U, Simonsen K. Recycling with nicotine patches in smoking cessation. Addiction. 1993;88:533-539.